| Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 |
HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-year adjusted EBITDA guidance, but potential equity offerings to manage debt remain a risk. HRTX's CEO speaks of Zynrelef's multi-hundred-million-dollar potential, although it may take several more quarters of sales growth to convince the market of that potential. |
seekingalpha.com |
2025-05-07 19:38:08 |
Czytaj oryginał (ang.) |
| Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript |
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Conference Call Participants Yuxi Dong - Jefferies Serge Belanger - Needham & Company Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call. |
seekingalpha.com |
2025-05-06 15:38:16 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-06 14:36:02 |
Czytaj oryginał (ang.) |
| Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates |
Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago. |
zacks.com |
2025-05-06 13:56:06 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates |
Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI ® and APONVIE ® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025 CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. |
prnewswire.com |
2025-05-06 11:45:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations |
— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related to CINVANTI® (aprepitant) injectable emulsion and APONVIE® (aprepitant) injectable emulsion. |
prnewswire.com |
2025-05-06 11:30:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release |
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:06:13 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer |
CARY, N.C. , April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. |
prnewswire.com |
2025-04-28 22:55:00 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms |
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio. |
zacks.com |
2025-04-23 14:35:35 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now |
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. |
zacks.com |
2025-04-23 13:55:52 |
Czytaj oryginał (ang.) |
| Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 |
CARY, N.C. , April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights. |
prnewswire.com |
2025-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for April 22nd |
DPMLF, HRTX and FOX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 22, 2025. |
zacks.com |
2025-04-22 15:15:38 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for April 22nd |
DPMLF, PAM, MTAL, HRTX and BALY have been added to the Zacks Rank #1 (Strong Buy) List on April 22, 2025. |
zacks.com |
2025-04-22 12:25:35 |
Czytaj oryginał (ang.) |
| Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript |
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Bill Forbes - Executive Vice President, Chief Development Officer Kevin Warner - Senior Vice President, Medical Affairs, Strategy and Engagement Conference Call Participants Brandon Folkes - Rodman & Renshaw Serge Belanger - Needham Carl Byrnes - Northland Capital Markets Clara Donald - Jefferies Operator Good day, and thank you for standing by, and welcome to the Heron Therapeutics Q4 2024 Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-27 14:07:02 |
Czytaj oryginał (ang.) |
| Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-27 12:35:50 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates |
Achieved Q4 2024 GAAP Net Income of $3.6 million Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year Delivered full-year 2024 adjusted EBITDA of $8.6 million Generated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024 U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi USA, LLC, and upheld the validity of CINVANTI® patents which expire in 2035 CARY, N.C. , Feb. 27, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2024, and highlighted recent corporate updates. |
prnewswire.com |
2025-02-27 09:45:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 |
CARY, N.C., Feb. 13, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 27, 2025, at 8:00 a.m. |
prnewswire.com |
2025-02-13 18:20:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina |
SAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. A majority of Heron's Management Team and corporate employees work from the Cary office, which is near the Research Triangle Park ("RTP"), one of the most prominent high-tech research and development parks in the United States. |
prnewswire.com |
2024-12-23 18:05:00 |
Czytaj oryginał (ang.) |
| Relief For Heron Therapeutics After The Court Win On Cinvanti |
Heron Therapeutics won a court case securing Cinvanti's patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on growing the business. Heron missed Q3 revenue estimates, but the company expects a recovery in Cinvanti sales in Q4 due to new account wins, and it shared encouraging trends of Zynrelef and Aponvie. |
seekingalpha.com |
2024-12-04 17:01:27 |
Czytaj oryginał (ang.) |
| U.S. District Court Upholds Validity of CINVANTI® Patents |
— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA, LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos. |
prnewswire.com |
2024-12-03 18:36:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript |
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President & Chief Financial Officer William Forbes - Executive Vice President & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Serge Belanger - Needham Brandon Folkes - Rodman & Renshaw Operator Thank you for standing by and welcome to Heron Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-12 13:45:22 |
Czytaj oryginał (ang.) |
| Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-11-12 13:00:38 |
Czytaj oryginał (ang.) |
| Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates |
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. |
zacks.com |
2024-11-12 12:11:08 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance |
Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launch CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient department and ambulatory surgical center settings of care SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2024, and highlighted recent corporate updates. "We are pleased to report that with our prudent financial management and continued revenue growth we were able to achieve positive Adjusted EBITDA for the quarter," said Craig Collard, Chief Executive Officer. |
prnewswire.com |
2024-11-12 09:55:00 |
Czytaj oryginał (ang.) |
| Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics |
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2024-11-07 12:21:04 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors |
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. |
prnewswire.com |
2024-11-04 19:00:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 |
SAN DIEGO , Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights. |
prnewswire.com |
2024-10-29 18:05:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids |
SAN DIEGO , Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE® for Postoperative Nausea and Vomiting ("PONV") prevention given the temporary shortage of intravenous ("IV") fluids which is expected as the result of Hurricane Helene. As alternatives to products that require dilution with IV fluids, CINVANTI, SUSTOL, and APONVIE are supplied in ready-to-administer formulations that do not require additional dilution with IV fluids in what may be a time of critical shortage. |
prnewswire.com |
2024-10-10 20:08:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") |
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. |
prnewswire.com |
2024-09-25 12:00:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer |
SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. |
prnewswire.com |
2024-09-03 12:00:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-08-07 00:31:04 |
Czytaj oryginał (ang.) |
| Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates |
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2024-08-06 23:46:29 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance |
Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent corporate updates. "We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success. |
prnewswire.com |
2024-08-06 20:05:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 |
SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights. |
prnewswire.com |
2024-07-30 20:05:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System |
SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") and the Medicare Ambulatory Surgical Center ("ASC") payment system (the "Proposed Rule") as a qualifying product effective April 1, 2025. This Proposed Rule for payment within hospital outpatient departments ("HOPDs") and ASCs was issued by the Centers for Medicare & Medicaid Services ("CMS"). |
prnewswire.com |
2024-07-15 12:00:00 |
Czytaj oryginał (ang.) |
| Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know |
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-07-11 17:02:33 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for July 11th |
SKIL, INKT, MLCO, GTLB, and HRTX have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2024. |
zacks.com |
2024-07-11 12:11:11 |
Czytaj oryginał (ang.) |